Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy – a real-world experience

Castro, Tiago B. R.; Jochheim, Leonie; Bathon, Melanie; Welland, Sabrina; Jeschke, Matthias; Ludwig, J M; Lange, C.-E.; Vogel, Arndt

doi:10.1055/s-0041-1740781

Cited by 1 publication

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5A). Ten studies [17,21,25,26,30,31,32,35,40,42] reported the complete mPFS data, and the pooled mPFS was 6.66 months (95% CI, 6.07-7.26, I2 = 0.0%, p = 0.973, Fig. 5B).…”

Section: Survivalmentioning

confidence: 99%

“…The IMbrave150 trial's inclusion criteria were as follows: no prior systemic therapy for advanced HCC; a Child-Pugh score (CPS) of A; and the score of the Eastern Cooperative Oncology Group (ECOG) was 0 or 1 [15]. Six studies [17,21,25,35,37,42] reported the OR of atezolizumab combined with bevacizumab treatment in the IMbrave-IN group who ful lled the inclusion criteria, and the pooled OR rate evaluated with RECIST was 30% (95% CI, 28-33%, I 2 = 5.13%, p = 0.38, Supplemental Fig. 4A).…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

“…4A). Two studies [21,37] reported the OR in the IMbrave-OUT group who met at least one of the exclusion criteria of the IMbrave150 study (patients receiving the combination treatment of atezolizumab and bevacizumab as non-rst-line therapy, a CPS of B, or ECOG ≥ 2) [21,37], and the pooled OR rate assessed with RECIST was 13% (95% CI, 6-19%, I 2 = 0.00%, Supplemental Fig. 4B).…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

“…Four studies [21,32,34,42] reported the complete mOS data for the combination treatment, and the pooled mOS was 14.70 months (95% CI, 11.39-18.01, I 2 = 80.5%, p = 0.002, Fig. 5A).…”

Section: Survivalmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a systematic review and single-arm meta-analysis

Gao

Zhao

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Atezolizumab plus bevacizumab was approved in 2020 as a first-line treatment for advanced hepatocellular carcinoma (HCC). The purpose of this study was to assess the curative effect and tolerability of the combination treatment in advanced HCC. Methods Web of Science, PubMed and Embase were retrieved for qualified literatures on the treatment of advanced HCC with atezolizumab plus bevacizumab until September 1, 2022. The outcomes included pooled overall response (OR), complete response (CR), partial response (PR), median overall survival (mOS), median progression-free survival (mPFS), and adverse events (AEs). Results Twenty-three studies, comprising 3168 patients, were enrolled. The pooled OR, CR, and PR rates of the long-term (more than six weeks) therapy response based on Response Evaluation Criteria in Solid Tumors (RECIST) were 26%, 2%, and 23%, respectively. The pooled OR, CR, and PR rates of the short-term (six weeks) therapeutic response evaluated with RECIST were 13%, 0%, and 15%, respectively. The pooled mOS and mPFS were 14.7 months and 6.66 months, respectively. During the treatment, 83% and 30% of patients experienced any grade AEs and grade 3 and above AEs, respectively. Conclusions Atezolizumab in combination with bevacizumab showed good efficacy and tolerability in the treatment of advanced HCC. Compared with short-term, non-first-line, and low-dose therapy, atezolizumab plus bevacizumab in long-term, first-line, and standard-dose treatment for advanced HCC showed a better tumor response rate.

show abstract

“…5A). Ten studies [17,21,25,26,30,31,32,35,40,42] reported the complete mPFS data, and the pooled mPFS was 6.66 months (95% CI, 6.07-7.26, I2 = 0.0%, p = 0.973, Fig. 5B).…”

Section: Survivalmentioning

confidence: 99%

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

“…Four studies [21,32,34,42] reported the complete mOS data for the combination treatment, and the pooled mOS was 14.70 months (95% CI, 11.39-18.01, I 2 = 80.5%, p = 0.002, Fig. 5A).…”

Section: Survivalmentioning

confidence: 99%

See 2 more Smart Citations